



CPhI worldwide

5-7 Nov 2019

Meet our representative
At Frankfurt, Germany



Mr. Rajkumar Agarwal -
Manager Business Development

To schedule a meeting write to us at Rajkumar.Agarwal@veedacr.com



INDIAN PHARMA

Indian pharma aims to corner 7% of global market by 2030



REGULATORY

Updated: Interchangeable biosimilars: FDA finalizes guidance



CLINICAL RESEARCH

Changing Paradigms in Clinical Trials, 2019-2050



FINANCIALS

The global clinical trials market size is expected to reach USD 68.9 billion by 2026



M & A

Pfizer, 'never say never' with big M&A, inks \$11.4B Array cancer deal



ARTICLE

Current regulatory landscape for drug approvals and clinical trials in India



REGULATORY

Updated:
Interchangeable
biosimilars: FDA
finalizes guidance

The FDA on Friday finalized a long-awaited guidance spelling out how biosimilars can achieve an interchangeable status, which means they may be substituted for the reference biologic without a prescriber intervening.
Read more: <https://endpts.com/fda-finalizes-guidance-on-interchangeable-biosimilars/>

FDA approved vs. FDA
cleared: Why you need to
know the difference

The Food and Drug Administration is responsible for telling us which foods, drugs and medical devices are safe for us to use. And while we assume that anything that's been cleared or approved by the FDA has been rigorously tested, that's not always true.
Read more: <https://www.cnet.com/news/fda-approved-vs-fda-cleared-whats-the-difference/>

USDA ANNOUNCES
PROPOSED RULE
UPDATING
BIOTECHNOLOGY
REGULATIONS

The USDA's Animal and Plant Health Inspection Service released a rule proposal that's designed to update its biotechnology regulations.
Read more: <https://www.nwsource.com/2019/06/07/usda-announces-proposed-rule-updating-biotechnology-regulations>

FDA Releases New Data to Help Generic Drug Competitors

Generic drug applicants will now have more information from the US Food and Drug Administration (FDA) when deciding whether to file a generic drug application, which could potentially increase the odds of earlier approvals, the agency said on Tuesday.

Read more: <https://www.raps.org/news-and-articles/news-articles/2019/6/fda-releases-new-data-to-help-generic-drug-competitors>

FDA Updates List of Off-Patent, Off-Exclusivity Drugs Without Generic Competition

Since 2017, the US Food and Drug Administration (FDA) has been striving to help generic companies understand which brand name drug products are no longer protected by patents or exclusivities and currently have no generic competitors

Read more: <https://www.raps.org/news-and-articles/news-articles/2019/6/fda-updates-list-of-off-patent-off-exclusivity-drugs>





FINANCIALS

Indian injectables maker KriGen to build \$7M plant in North Carolina

KriGen Pharmaceuticals, an India-based injectables maker, unveiled plans to build a \$7 million facility in Lillington, North Carolina.
Read more : <https://www.fiercepharma.com/manufacturing/indian-injectables-maker-krigen-to-build-7m-plant-north-carolina>

Branded Generics Market to register high revenue growth at 7.3% CAGR during 2016-2026

Differential and innovative product strategies that are adopted by various multinational pharma companies have been fuelling the growth of branded generics market at a global scale.
Read more : <https://www.wikitimes.co.uk/2019/06/05/branded-generics-market-to-register-high-revenue-growth-at-7-3-cagr-during-2016-2026/>

25.8 billion earmarked for AI-driven drug discovery

The Korean government said it would spend 25.8 billion won (\$21.7 million) on supporting the discovery and development of innovative medicines using artificial intelligence (AI) in the next three years.
Read more : <http://www.koreabiomed.com/news/articleView.html?idxno=5924>

CNH Partners LLC Takes \$10.73 Million Position in ANDINA ACQUISIT/SH SH (NASDAQ:ANDA)

CNH Partners LLC acquired a new stake in ANDINA ACQUISIT/SH SH (NASDAQ:ANDA) during the 1st quarter, according to the company in its most recent filing with the SEC.
Read more : <https://techknowbits.com/2019/06/16/cnh-partners-llc-takes-10-73-million-position-in-andina-acquisit-sh-sh-nasdaqanda.html>

Indian Pharma industry aspiring to grow to \$120-130 billion by 2030: IPA

NEW DELHI: The Indian pharmaceutical industry is aspiring to touch USD 120-130 billion by 2030 from the current USD 38 billion, industry body Indian Pharmaceutical Alliance (IPA) said on Wednesday.
Read more : https://economictimes.indiatimes.com/articleshow/69861213.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst



CLINICAL RESEARCH

Enhancing Clinical Trial Participation

Having worked as a research nurse, I have heard an abundance of reasons for low attrition from both providers and patients. Physicians in busy office practices have time constraints limiting their availability to explain the nature of trials. A lack of research personnel in the ambulatory setting is also a barrier.

Read more : <https://www.0ncnursingnews.com/contributor/debi-boyle/2019/06/enhancing-clinical-trial-participation>

The top 10 drug launches of 2019

As part of CEO Ludwig Hantson's plan for Alexion to pivot away from ultrarare diseases and reach more patients, the biotech has priced Ultomiris at a 10% discount to Soliris and is aiming to convert 70% of Soliris patients to the improved therapy. Paroxysmal nocturnal hemoglobinuria (PNH), the current condition Ultomiris is approved in, is a rare disease that involves the immune system.

Read more : <https://www.fiercepharma.com/special-report/top-10-drug-launches-2019>

Accelerating drug development at a lower cost: How adopting AI can transform the pharma industry

To combat the complex drug discovery process, medical industry is organising steps to adapt the futuristic technologies like AI to step in to generate new ideas, hypotheses, design experiments and accelerate the scientific process, informs Dr Neeraj Mahindroo, Dean, School of Health Sciences, UPES

Read more : <http://www.expressbpd.com/pharma/latest-updates/accelerating-drug-development-at-a-lower-cost-how-adopting-ai-can-transform-the-pharma-industry/409768/>

Five Tips for Evaluating Clinical Studies

Evaluating the results of clinical studies can be daunting, but some simple tools can make it a fun experience. I consider drug literature evaluation to be a journey down a somewhat winding road that ultimately leads to a better understanding of a clinical study.

Read more : <https://www.drugtopics.com/latest/five-tips-evaluating-clinical-studies>

Changing Paradigms in Clinical Trials, 2019-2050

The process of developing novel and effective healthcare products is both cost and time intensive. Studies suggest that each prescription drug requires around 10 years and over USD 2.5 billion in working capital before it reaches the market. Further, it is estimated that, in the US, 40% of the pharma industry's R&D budget is spent solely on conducting clinical trials.

Read more : <https://finance.yahoo.com/news/changing-paradigms-clinical-trials-2019-200100390.html>





MERGER AND ACQUISITION

PharmaCielo to acquire Creso Pharma for \$122m.

Canadian listed company PharmaCielo has launched a takeover bid for Creso Pharma (ASX: CPH), which Creso's board endorses and values the company at A\$122 million.

Read more : <https://smallcaps.com.au/pharmacielo-acquisition-creso-pharma-122m/>

Pfizer, 'never say never' with big M&A, inks \$11.4B Array cancer deal

In the first big M&A deal under new CEO Albert Bourla, Pfizer has agreed to buy oncology specialist Array BioPharma for a total value of about \$11.4 billion, the two companies unveiled Monday. The \$48-per-share offer represents a premium of about 62% to Array stock's closing price on Friday.

Read more : <https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b>

Gryphon-Backed Water's Edge Dermatology Acquires Coast Dermatology

Water's Edge Dermatology ("Water's Edge" or "the Company"), a leading provider of comprehensive dermatology services through 37 Florida locations, announced today that it has acquired a controlling interest in Coast Dermatology ("Coast"), a medical/cosmetic dermatology practice in Venice, Florida. Terms of the transaction were not disclosed.

Read more : <https://finance.yahoo.com/news/gryphon-backed-waters-edge-dermatology-110000318.html>

Mundipharma inks biosimilars deal with Egis Pharma

Mundipharma has entered into an exclusive distribution agreement with Egis Pharmaceuticals for Pelmeg, a pegfilgrastim biosimilar treatment. The agreement covers Hungary, Romania, Latvia and Lithuania, where Mundipharma does not have a direct commercial presence.

Read more : <https://www.thepharmaletter.com/article/mundipharma-inks-biosimilars-deal-with-egis-pharma>

Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma

HAMILTON, N.J., June 18, 2019 /PRNewswire/ -- Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) of Genesis Biotechnology Group® (GBG), announced that it has expanded its drug development services through the acquisition of a majority interest in NexusPharma

Read more : <https://www.prnewswire.com/news-releases/genesis-drug-discovery--development-expands-preclinical-contract-research-portfolio-by-acquiring-nexuspharma-300869712.html>



INDIAN PHARMA

Indian e-pharma market poised to touch US\$2.7 billion by 2023: EY

According to a new EY report 'e-pharma: delivering healthier outcomes', e-pharma players are expected to attain a combined market size of US\$2.7 billion by 2023 from about US\$360 million currently in the next four years.

Read more : https://www.equitybulls.com/admin/news2006/news_det.asp?id=251784

GSP withdrawal by US may have marginal impact on Indian pharma exporters

The withdrawal of the Generalized System of Preferences (GSP) benefits by the US could have an impact of 4-5 percent on margins of Indian pharmaceutical companies exporting drugs to the country.

Read more : <https://www.moneycontrol.com/news/business/companies/gsp-withdrawal-by-us-may-have-marginal-impact-on-indian-pharma-exporters-4059841.html>

Pharmaceutical intermediates market to see growth

This is according to a new report by Future Market Insights which states that the global sales of pharmaceutical intermediates closed in on US\$26 billion 2018.

Read more : <https://www.europeanpharmaceuticalreview.com/news/89498/pharmaceutical-intermediates-market-growth/>

Indian pharma aims to corner 7% of global market by 2030

The Indian pharmaceutical industry aspires to have a 7 percent share in the global drug market by 2030, a joint report by the Indian Pharmaceutical Alliance (IPA) and McKinsey said.

Read more : <https://www.moneycontrol.com/news/business/companies/indian-pharma-aims-to-corner-7-of-global-market-by-2030-report-4120651.html>

Govt may make barcoding compulsory for all medicines sold in country: Report

The Central Drugs Standards Control Organization (CDSCO) is considering making barcoding mandatory on all medicines sold within India to curb sale of counterfeit medicines, according to a Mint report.

Read more : <https://www.moneycontrol.com/news/economy/policy/govt-may-make-barcoding-compulsory-for-all-medicines-sold-in-country-report-4081341.html>



VEEDA CLINICAL RESEARCH® PVT. LTD.

Corporate Office

Veeda House, Beside YMCA club S.G.,
Highway, Vejalpur, Ahmedabad- 380015
Gujarat, India



Registered Office

Shivalik Plaza-A, Near IIM Ambawadi,
Ahmedabad- 380015, Gujarat, India.
CIN No. U73100GJ2004PTC044023



Other Office

Insignia, Besides Auda Garden, Opp. Zenobia
Residency, Sindhu Bhavan Road, Off. S. G. Highway,
Bodakdev, Ahmedabad- 380059, Gujarat, India

For more Information and Business Inquiry contact us at



+91 79 3001 3000



info@veedacr.com

Follow us at:



Disclaimer: "The information compiled and published in this newsletter has been sourced, collected and derived from various resources which are in the public domain available on the web and relevant sites. Veeda makes no claims, promises or guarantees about the accuracy, completeness, or adequacy of the contents of the newsletters and expressly disclaims liability for errors and omissions in the contents of this newsletter. The intent and object of this Newsletter is to only disseminate scientific information for knowledge up-gradation. The transmission or reproduction of any items covered in this newsletter beyond that allowed by fair use as defined in the copyright laws may require the written permission of the copyright owners, if any. Neither Veeda, nor its employees and contractors make any warranty, expressed or implied or statutory, including but not limited to the warranties of non-infringement of third party rights, title, and the warranties of merchantability and fitness for a particular purpose with respect to content available from the newsletters. This is not a service by Veeda Clinical Research and it does not hold any responsibility for the accuracy of the news/information provided herein."